Fig. 1

DCBLD1 promotes cervical cancer progression in vivo and in vitro. A IHC staining for DCBLD1 was performed on tumor sections of human cervical cancer and adjacent normal tissue. Subsequently, H-scores were plotted. n = 50. B Immunoblotting was used to assess DCBLD1 levels in lysates extracted from various cell lines, including human normal cervical epithelial (HcerEpic) and cervical cancer (HeLa, C33A, and SiHa) cells. GAPDH and Tubulin are used as loading controls. The graph on the right is a statistical plot of the western blot. C, E The cell proliferation rate was determined using a clone formation assay. D, F Cell viability was determined using CCK8 assays. G Xenograft tumor images derived from HeLa cells. n = 5 mice per group. Tumor growth curves of the different groups. Weight of the excised tumors in each group. H Sections of tumor tissue from the xenograft tumor model were subjected to PCNA staining. I–J Transwell migration and invasion assays were performed on HeLa and C33A cells, stably expressing shCtrl, shDCBLD1, vector, and OV-DCBLD1. Data are presented as mean ± SD. Statistical significance was assessed using an unpaired t test (for panels A, C–F, and G for tumor volume, as well as I–J), a one-way ANOVA with Dunnett's multiple comparisons test (B), or a one-way ANOVA with the Brown-Forsythe test (G for tumor weight). (****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05).Scale bar: 50 µm